Evaluating Chemical CDK Inhibitors as Cell Death Inducers

  • Hiroshi HiraiEmail author
  • Yoko Nakatsuru
Part of the Methods in Molecular Biology book series (MIMB, volume 1336)


The cell cycle of eukaryotic cells is regulated by a family of protein kinases called cyclin-dependent kinases (Cdks). We have reported the identification and biological characterization of a highly potent, small-molecule pan-Cdk inhibitor, which inhibited Cdk1, 2, 4, 5, 6, and 9 with equal potency in the nM range. This compound inhibited multiple events in the cell cycle and induced cell death in human cancer cell lines as well as in peripheral blood or purified resting lymphocytes ex vivo. We describe the materials and methods to determine antitumor efficacy in vivo xenograft models. Pharmacodynamic marker assays that have been performed using tumors and normal tissues are explained. Moreover, we briefly describe methods for determining the effects of chemical Cdk inhibitors on peripheral blood cells or lymphocytes ex vivo.

Key words

Antitumor efficacy Cdk inhibitor Immunohistochemistry (IHC) assay In vivo xenograft model In vivo pharmacodynamics (PD) assay Lymphocytes Peripheral blood cells 


  1. 1.
    Sherr CJ (1996) Cancer cell cycles. Science 274:1672–1677PubMedCrossRefGoogle Scholar
  2. 2.
    Sherr CJ (2000) The Pezcoller lecture: cancer cell cycles revised. Cancer Res 60:3689–3695PubMedGoogle Scholar
  3. 3.
    Pines J (1995) Cyclins and cyclin-dependent kinases: theme and variations. Adv Cancer Res 66:181–212PubMedCrossRefGoogle Scholar
  4. 4.
    Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512PubMedCrossRefGoogle Scholar
  5. 5.
    Pavletich NP (1999) Mechanism of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and CIP and INK4 inhibitors. J Mol Biol 287:821–828PubMedCrossRefGoogle Scholar
  6. 6.
    Koepp DM, Haper JW, Elledge SJ (1999) How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 97:431–434PubMedCrossRefGoogle Scholar
  7. 7.
    Falco GD, Giordan A (1998) CDK9 (PITALRE): a multifunctional cdc2-related kinase. J Cell Physiol 177:501–506PubMedCrossRefGoogle Scholar
  8. 8.
    Palancade B, Bensaude O (2003) Investigating RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation. Eur J Biochem 270:3859–3870PubMedCrossRefGoogle Scholar
  9. 9.
    Price DH (2000) P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 20:2629–2634PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Dhavan R, Tsai L-H (2001) A decade of CDK5. Nat Rev Mol Cell Biol 2:749–759PubMedCrossRefGoogle Scholar
  11. 11.
    Lilja L, Yang S, Webb D et al (2001) Cyclin-dependent kinase 5 promotes insulin exocytosis. J Biol Chem 276:34199–34205PubMedCrossRefGoogle Scholar
  12. 12.
    Hirai H, Takahashi-Suzuki I, Shimomura T et al (2011) Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo. Invest New Drugs 29:534–543PubMedCrossRefGoogle Scholar
  13. 13.
    Kobayashi M, Takahashi-Suzuki I, Shimomura T et al (2011) Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor. Invest New Drugs 29:921–931PubMedCrossRefGoogle Scholar
  14. 14.
    Hirai H, Shimomura T, Kobayashi M et al (2010) Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo. Cell Cycle 9:1590–1600PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2016

Authors and Affiliations

  1. 1.Taiho Pharmaceutical Co. Ltd.Tsukuba Research CenterTsukubaJapan

Personalised recommendations